The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): Post hoc analysis of the phase III ARCHES trial.
 
Arun Azad
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Merck Serono; Novartis; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); MedImmune (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen; Merck Serono; Sanofi
 
Arnauld Villers
Consulting or Advisory Role - Astellas Pharma
Research Funding - Astellas Pharma (Inst); Janssen Oncology (Inst)
 
Boris Alekseev
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ferring; Janssen; Merck; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ferring; Janssen; Merck; Pfizer; Sanofi
Research Funding - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Bristol-Myers Squibb; ICON Clinical Research; Janssen; Merck; Pfizer; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Sanofi
 
Russell Zelig Szmulewitz
Honoraria - Astellas Pharma
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi
Research Funding - Abbvie; Astellas Pharma; Incyte; Janssen Oncology; Macrogenics
Patents, Royalties, Other Intellectual Property - Patent licensed by University of Chicago of which I am co-inventor to Corcept Therapeutics for combination AR/GR inhibition in prostate cancer
Travel, Accommodations, Expenses - Corcept Therapeutics
 
Antonio Alcaraz
No Relationships to Disclose
 
Neal D. Shore
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Merck; Myovant Sciences; Pfizer; Tolmar
Speakers' Bureau - Bayer; Dendreon; Janssen
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Ipsen; Janssen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi
 
Jeffrey Holzbeierlein
Research Funding - MDxHealth (Inst)
(OPTIONAL) Uncompensated Relationships - Astellas Medivation
 
Francisco Gomez-Veiga
Honoraria - Abbvie; Astellas Pharma; AstraZeneca; Bayer; Ferring; GE Healthcare; GlaxoSmithKline; Ipsen; Janssen; Sanofi
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Bayer; Ferring; GE Healthcare; GlaxoSmithKline; Ipsen; Janssen; Sanofi
Research Funding - Abbvie; Astellas Pharma; AstraZeneca
 
Brad Rosbrook
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Fabian Zohren
Employment - Pfizer
Stock and Other Ownership Interests - AlloVir (I); Pfizer
 
Ho-Jin Lee
Employment - Astellas Pharma
Stock and Other Ownership Interests - Abbvie; Acadia Pharmaceuticals; AcelRx; Sarepta Therapeutics
 
Gabriel P. Haas
Employment - Astellas Pharma
 
Taro Iguchi
Consulting or Advisory Role - Astellas Pharma; Bayer Yakuhin; Janssen
Speakers' Bureau - Astellas Pharma; Bayer Yakuhin; Janssen; Sanofi
Research Funding - Astellas Pharma; Bayer Yakuhin
 
Arnulf Stenzl
Consulting or Advisory Role - Alere; Bristol-Myers Squibb; Ferring; Ipsen; Janssen; Roche; Steba Biotech; Synergo
Research Funding - Amgen (Inst); Astellas Pharma; AstraZeneca; Bayer (Inst); Cepheid (Inst); GenomeDx (Inst); immatics (Inst); Janssen; Johnson & Johnson (Inst); Karl Storz (Inst); Medivation; Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - 2018/6579 Gene-expression signature for subtype and prognostic prediction of renal cell carcinoma; AT00/0001:C-Trap, implantable device to treat urinary incontinence; Patent A290/99 Implantable incontinence device
Expert Testimony - GBA Pharma
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; CureVac; Ferring; Ipsen; Janssen; Sanofi/Aventis
 
Andrew J. Armstrong
Honoraria - Astellas Scientific and Medical Affairs Inc
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; Dendreon; Merck; Pfizer
Speakers' Bureau - Bayer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc